Details for Patent: 7,767,678
✉ Email this page to a colleague
Which drugs does patent 7,767,678 protect, and when does it expire?
Patent 7,767,678 protects BOSULIF and is included in two NDAs.
Protection for BOSULIF has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has twenty-five patent family members in twenty-five countries.
Summary for Patent: 7,767,678
| Title: | Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-pipera- zinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same |
| Abstract: | This invention is directed to a crystalline 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-pipera- zinyl)propoxy]-3-quinolinecarbonitrile monohydrate having an x-ray diffraction pattern wherein 2.theta. angles (.degree.) of significant peaks are at about: 9.19, 11.48, 14.32, 19.16, 19.45, 20.46, 21.29, 22.33, 23.96, 24.95, 25.29, 25.84, 26.55, 27.61, and 29.51, and a transition temperature of about 109.degree. C. to about 115.degree. C. |
| Inventor(s): | Tesconi; Marc Sadler (Monroe, NY), Feigelson; Gregg (Chester, NY), Strong; Henry (Somerset, NJ), Wen; Hong (Westfield, NJ) |
| Assignee: | Wyeth LLC (Madison, NJ) |
| Application Number: | 11/478,216 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,767,678 |
|
Patent Claim Types: see list of patent claims | Compound; Use; Composition; |
More… ↓ |
Drugs Protected by US Patent 7,767,678
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pf Prism Cv | BOSULIF | bosutinib monohydrate | CAPSULE;ORAL | 217729-001 | Sep 26, 2023 | RX | Yes | No | 7,767,678*PED | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Pf Prism Cv | BOSULIF | bosutinib monohydrate | CAPSULE;ORAL | 217729-002 | Sep 26, 2023 | RX | Yes | Yes | 7,767,678*PED | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Pf Prism Cv | BOSULIF | bosutinib monohydrate | TABLET;ORAL | 203341-001 | Sep 4, 2012 | RX | Yes | Yes | 7,767,678*PED | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Pf Prism Cv | BOSULIF | bosutinib monohydrate | TABLET;ORAL | 203341-003 | Oct 27, 2017 | RX | Yes | No | 7,767,678*PED | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Pf Prism Cv | BOSULIF | bosutinib monohydrate | TABLET;ORAL | 203341-002 | Sep 4, 2012 | RX | Yes | No | 7,767,678*PED | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,767,678
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1902029 | ⤷ Subscribe | C20140016 00110 | Estonia | ⤷ Subscribe |
| Argentina | 054505 | ⤷ Subscribe | |||
| Australia | 2006266045 | ⤷ Subscribe | |||
| Brazil | PI0613574 | ⤷ Subscribe | |||
| Canada | 2613053 | ⤷ Subscribe | |||
| China | 101248047 | ⤷ Subscribe | |||
| Costa Rica | 9596 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
